Figure 3From: The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantationTelomerase inhibition therapies utilized in the treatment of hematologic malignancies. Telomerase-based immunotherapies utilize telomerase-associated antigens to produce an immune response which ultimately leads to lysis of tumor cells. Tyrosine kinase inhibitors (TKI), arsenic trioxide (ATO), interferon alpha (IFN-α) and interferon gamma (IFN-γ) reduce the expression of hTERT; imetelstat (GRN163) is complementary to the template region of the telomerase RNA component hTERC, competitively binding and blocking telomerase; BIBR1532 inhibits the specific active site of hTERT.Back to article page